trending Market Intelligence /marketintelligence/en/news-insights/trending/x3mwebzUOYD7Vvap_FlhdA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis launches 1st generic version of United Therapeutics' Remodulin in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis launches 1st generic version of United Therapeutics' Remodulin in US

Swiss drugmaker Novartis AG's unit Sandoz Inc. said it launched the first generic version of United Therapeutics Corp.'s blood pressure drug Remodulin in the U.S.

Remodulin, also called treprostinil, is used to treat pulmonary arterial hypertension, or PAH, a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The disease mainly affects women.

Sandoz said the copycat launched with 180 days of marketing exclusivity, which is part of the U.S. Food and Drug Administration's effort to encourage generic competition.

The exclusivity is granted to the first generic drug applicant to submit a substantially complete generic application that includes a challenge to the brand-name drug's patents.

According to Sandoz, about 52,000 patients have been diagnosed with the disease in the U.S., with rates expected to rise due to increased survival and diagnosis.

Sandoz said it will partner with RareGen LLC to commercialize treprostinil injection in the U.S. Silver Spring, Md.-based United Therapeutics reported global sales of $599 million from treprostinil in 2018.

In 2018, United Therapeutics bought SteadyMed Ltd. after the San Ramon, Calif.-based company won a ruling invalidating one of United's patents related to Remodulin.